Brief: Wave Life Sciences Remains On Track To Deliver Proof-Of-Mechanism Data Measured By Restoration Of M-AAt Protein In Serum
30/04/2024 14:10
April 30 (Reuters) - WAVE Life Sciences Ltd WVE.O :
* WAVE LIFE SCIENCES ANNOUNCES APPROVAL OF FIRST CLINICAL
TRIAL
APPLICATION FOR RESTORAATION-2 TRIAL OF WVE-006 IN INDIVIDUALS
WITH ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
* WAVE LIFE SCIENCES LTD: DEVELOPMENT AND COMMERCIALIZATION
RESPONSIBILITIES WILL TRANSFER TO GSK AFTER WAVE COMPLETES
RESTORAATION-2 STUDY FOR WVE-006
* WAVE LIFE SCIENCES LTD: REMAINS ON TRACK TO DELIVER
PROOF-OF-MECHANISM DATA, AS MEASURED BY RESTORATION OF M-AAT
PROTEIN IN SERUM, IN 2024
Source text for Eikon: ID:nGNX7zcFq7
Further company coverage: WVE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wave Life Sciences
See all newsWave Life Sciences Ltd Reports Results For The Quarter Ended June 30: Earnings Summary
Wave Life Sciences Ltd Expected To Post A Loss Of 31 Cents A Share: Earnings Preview
Wave Life Sciences Q1 revenue jumps, beats analyst estimates
Brief: Wave Life Sciences Announces Hearing On Proposed Redomiciliation To The United States
Brief: Wave Life Sciences Announces Proposed Redomiciliation To The United States